ArticleGynecologic oncology2014
A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
Article in Gynecologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 66 citations in OpenAlex.
- The Ultrasonography Characteristics of Borderline Ovarian Tumor Subtypes.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025Article
- Molecular changes driving low-grade serous ovarian cancer and implications for treatment.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Review
- KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Virchows Archiv : an international journal of pathology · 2023Article
- Risk of nonovarian cancer in a nationwide-based study of nearly 5000 women with borderline ovarian tumors in Denmark.International journal of cancer · 2023Article
- Identification of clinical and molecular features of recurrent serous borderline ovarian tumour.EClinicalMedicine · 2022Article
- SuccessfulGynecologic oncology reports · 2021Article
- The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.International journal of cancer · 2020Article
- Article
- Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.The American journal of surgical pathology · 2019Article
- [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].Der Pathologe · 2019Review
- KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.Human pathology · 2017Article
- Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.The American journal of surgical pathology · 2017Article
- Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Virchows Archiv : an international journal of pathology · 2017Review
- A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.Gynecologic oncology · 2017Article
- Fine needle aspiration cytology of cervical lymph node involvement by ovarian serous borderline tumor.CytoJournal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveTo describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population.
methodsThe Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013.
resultsA cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p=0.3), whereas women with advanced stage disease had a poorer one (p<0.0001). This was evident both in women with noninvasive (p<0.0001) and invasive implants (p<0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p<0.0001) and noninvasive LGSC (p<0.0001) was poorer than expected from the general population.
conclusionsTo date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.